Skip to main content

Table 2 Controller medication of asthma patients before anti-IL5/IL5R and anti-IgE therapy

From: A comparison of biologicals in the treatment of adults with severe asthma – real-life experiences

Controller medication before biologicals Anti-IL5/IL5R (reslizumab, mepolizumab or benralizumab), n = 42 Anti-IgE (omalizumab), n = 22
ICS daily dose (number, (%)) a
High 41 (98) 20 (91)
Intermediate 1 (2) 2 (9)
Low 0 (0) 0 (0)
Daily use of long acting beta-agonist (number, (%)) 41 (98) 19 (86)
Daily use of theophylline (number, (%))b 7 (17) 7 (32)
Daily use of montelukast (number, (%)) c 30 (71) 13 (59)
Daily use of long-acting anticholinergic (number, (%)) 27 (64) 15 (68)
Daily use of one asthma controller medication in addition to ICS (number, (%)) 7 (17) 4 (18)
Daily use of two or more asthma controller medications in addition to ICS (number, (%)) 35 (83) 18 (82)
Daily use of OCS (number, (%)) 30 (71) 10 (45)
  1. aICS = inhaled corticosteroid. For beclomethasone and budesonide: low dose 0–399 μg/day, intermediate dose 400–799 μg/day and high dose 800 μg/day or more, for fluticasone low dose 0–249 μg/day, intermediate dose 250–499 μg/day and high dose 500 μg/day or more, and for ciclesonide low dose 0–159 μg/day, intermediate dose 160–319 μg/day and high dose 320 μg/day or more. The ICS daily dose was defined as the dose prior to initiation of biological therapy
  2. bAdditionally, 3 patients in the reslizumab group, 5 patients in the mepolizumab group and 3 patients in the omalizumab group had received theophylline earlier but discontinued it because of lack of response or side effects
  3. cAdditionally, 1 patient in the reslizumab group, 3 patients in the mepolizumab group and 6 patients in the omalizumab group had received montelukast earlier but discontinued it because of lack of response or side effects